Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in September 2000, RiverVest Venture Partners is a venture capital firm based in St. Louis, Missouri, with additional offices in San Diego, California, and Cleveland, Ohio. The firm specializes in building life science companies that address significant unmet medical needs, managing a portfolio with notable exits and a strong investor syndicate.
RiverVest invests primarily in the biopharma and medical device sectors, targeting seed, Series A, Series B, and growth equity stages. The firm emphasizes products with a known path to clinical approval and aims to demonstrate safety and efficacy in early clinical trials. Their strategy includes leading financings and founding companies while effectively managing risk to achieve high hit rates.
Notable portfolio companies include: Good Therapeutics: Acquired by Roche in 2022 for $250 million upfront, with potential milestone payments. Standard Bariatrics: Acquired by Teleflex in 2022 for $170 million plus additional milestone payments. Lumena Pharmaceuticals: Co-founded by RiverVest, acquired by Shire in 2014, focusing on therapies for rare liver disease.
To pitch RiverVest, email info@rivervest.com with your deck and a brief overview of your company.
Yes, RiverVest typically leads financings, which allows them to shape the direction of the companies they invest in.
RiverVest is open to follow-on investments, particularly in companies that demonstrate strong progress in clinical trials and market potential.
Specific fund size details are not disclosed, but RiverVest has a history of managing significant capital for investments in the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.